Minor
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
Primary and study completion pushed from Sep 2026 to Nov 2026
Miltenyi Biomedicine GmbHPhase 1 NCT03853616 Registry history of NCT03853616 on ClinicalTrials.gov (opens the registry)
Updated
15 active trials 12 recruiting 12 disease areas 2 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Primary and study completion pushed from Sep 2026 to Nov 2026
Miltenyi Biomedicine GmbHPhase 1 NCT03853616 Registry history of NCT03853616 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 2 | |
| Phase 1/2 | 4 | |
| Phase 2 | 5 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting | 2026-07-13 |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | Diffuse Large B-cell Lymphoma | Recruiting | 2026-06-10 |
| NCT06508931 | Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric… | B-Cell Neoplasm | Recruiting | 2026-05-05 |
| NCT07288879 | DALY II Japan/MB-CART2019.1 for DLBCL | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting | 2026-01-08 |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in… | Mantle Cell Lymphoma (MCL) | Not Yet Recruiting | 2026-05-06 |
| Phase 1/2 | ||||
| NCT07178431 | MB-CART2019.1 in Refractory Multiple Sclerosis | Multiple Sclerosis | Recruiting | 2026-05-11 |
| NCT06424340 | MB-dNPM1-TCR.1 in Relapsed/Refractory AML | Leukemia, Myeloid, Acute | Recruiting | 2026-04-16 |
| NCT06189157 | MB-CART19.1 in Refractory SLE | SLE - Systemic Lupus Erythematosus | Recruiting | 2025-11-26 |
| NCT06347718 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | Systemic Lupus Erythematosus | Recruiting | 2025-09-30 |
| Phase 1 | ||||
| NCT06708845 | US Zamto-cel Autoimmune Diseases | Lupus Nephritis | Recruiting | 2026-06-11 |
| NCT03853616 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Acute Lymphoblastic Leukemia Recurrent | Active, Not Recruiting | 2026-10-09 |
| Not applicable | ||||
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies | Melanoma Stage III | Recruiting | 2026-10-09 |
| NCT06225050 | M-2018-334 in Hematological Malignancies | Hematological Malignancies | Recruiting | 2026-09-11 |
| Not specified | ||||
| NCT06116110 | Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | Non Hodgkin Lymphoma | Recruiting | 2026-08-05 |
| NCT07717164 | PRAISE-IR Versus CIBMTR Controls | ALL (Acute B-Lymphoblastic Leukemia) | Not Yet Recruiting | 2026-07-28 |
Non-Hodgkin Lymphoma (6) · DLBCL (4) · Leukemia (4) · Acute Lymphoblastic Leukemia (ALL) (3) · Lupus (SLE) (3) · Acute Myeloid Leukemia (AML) (2) · Chronic Lymphocytic Leukemia (CLL) (2) · Mantle Cell Lymphoma (2) · Scleroderma (2) · Melanoma (1)